FDA official: The risk of secondary cancer from CAR-T therapy is less than feared
The risk of secondary cancer after CAR-T therapy, pioneered at Penn, is less than regulators feared last year, an FDA official said June 14 at cell and gene therapy conference in King of Prussia.
Jun 17, 2024
0
2